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Available online 25 October 2014We assessed the feasibility of developing a suitable international reference standard for
determination of in vitro biological activity of human sequence recombinant PEG-G-CSF products
with a 20 kD linear PEG linked to the N-terminal methionyl residue of G-CSF (INN Filgrastim),
produced using a conjugation process and coupling chemistry similar to that employed for the lead
PEGfilgrastim product. Based on initial data which showed that the currentWHO 2nd international
standard, IS for G-CSF (09/136) or alternatively, a PEG-G-CSF standard with a unitage traceable to
the G-CSF IS may potentially serve as the IS for PEG-G-CSF products, two candidate preparations of
PEG-G-CSF were formulated and lyophilized at NIBSC. These preparations were tested by 23
laboratories using in vitro bioassays in a multi-centre collaborative study. Results indicated that on
the basis of parallelism, the current WHO 2nd IS for G-CSF or any of the PEG-G-CSF samples could
be used as the international standard for PEG-G-CSF preparations. However, because of the
variability in potency estimates seen when PEG-G-CSF preparations were compared with the
currentWHO2nd IS for G-CSF, a candidate PEG-G-CSFwas suitable as theWHO IS. The preparation
12/188 was judged suitable to serve as the WHO IS based on in vitro biological activity data.
Therefore, the preparation coded 12/188 was established by the WHO Expert Committee on
Biological Standardization (ECBS) in 2013 as the WHO 1st IS for human PEGylated G-CSF with an
assigned in vitro bioactivity of 10,000 IU per ampoule.
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Modified G-CSF1. Introduction
Granulocyte-colony stimulating factor (G-CSF) is used
therapeutically for several indications relating to neutropenia
and increasingly for stemcellmobilization. As a result, there are
several recombinant human G-CSF approved products (INN
Filgrastim — Escherichia. coli expressed; INN Lenograstim —Factors Section, Bio-
Products Regulatory
rtfordshire, EN6 3QG,
hwa).
ier B.V. All rights reserved.CHO cell expressed) in clinical use. Due to the short half-life of
G-CSF which requires repeated administration (Möhle and
Kanz, 2007), several long-acting recombinant G-CSF forms
produced using different technologies are in development
worldwide. These include polyethylene glycol (PEG) conjugat-
ed G-CSF, G-CSF fused to proteins with long half-lives such as
albumin, the Fc fragment of IgGs or to polymers (Zhai et al.,
2009; Huang et al., 2010; Cox et al., 2014; Volovat et al., 2014).
Two PEG conjugated G-CSF products which have different
INNs (INN PEGfilgrastim, brand name — Neulasta; INN —
lipegfilgrastim, brand name— Lonquex) are already approved;
their use is limited to neutropenia and related indications (but
not stem cell-mobilization). While the lipegfilgrastim product
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Fig. 1. Comparison of PEG-G-CSF preparations (S, V and Z) relative to the
current IS for G-CSF (09/136) using the GNFS-60 cell-line.
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attachment of a 20 kD PEG molecule via a glycolinker to the
natural O-glycosylation site at the threonine residue (Thr134)
of Filgrastim (Lonquex EPAR assessment report, EMA), the
PEGfilgrastim has a 20 kDmonomethoxy PEG at theN-terminal
methionyl residue of Filgrastim (Neulasta EPAR assessment
report, EMA; Molineux, 2004; Kinstler et al., 1996).
As patent expiry is imminent for the PEGfilgrastim product,
several ‘copy’ PEGylated G-CSF products have entered the
market in poorly regulated countries while biosimilar and
novel molecules are in clinical development worldwide. While
the copy and biosimilar versions are likely to employ PEG
molecules of similar size and form and target the same site and
use the same coupling chemistry as the reference product
(Neulasta), novel products are likely to use PEG molecules
of different sizes, forms, and potentially target different
site(s) and employ different chemistries (Veronese et al.,
2007; Zhai et al., 2009; Maullu et al., 2009; Huang et al.,
2010). Depending on the size and shape of PEG chains attached
to G-CSF and the amino acid ligation sites in the product, the
biological properties of PEGylated products may differ signif-
icantly from the parental or unmodified G-CSF (Veronese et al.,
2007; Zhai et al., 2009; Maullu et al., 2009; Huang et al., 2010).
While it is assumed that manufacturers have measured the
potency of their PEG-CSF products in bioassays calibrated using
the standard available for the parent molecule i.e., current
WHO 2nd IS for G-CSF (09/136), the suitability of reporting
potencies in the respective IU has not been formally
established. As practices are likely to vary between manufac-
turers, this may result in availability of products (particularly
copy products including biosimilars as patent expiry is
imminent) with discrepant bioactivities. A reference standard
is, therefore required for determination of biological activity of
these products.
Since there is intense activity in the development of copy/
biosimilar versions of the PEGfilgrastim product (lead
marketed product), we concentrated our efforts on assessing
the feasibility of developing a suitable reference standard for
determination of biological activity of PEGylated G-CSF prod-
ucts which have a 20 kD linear PEG linked to the N-terminal
methionyl residue of G-CSF, INN Filgrastim and are produced
using a conjugation process and coupling chemistry similar to
that employed for the lead PEGfilgrastim product. Therefore,
we initially evaluated the biological activity of several PEG-G-
CSF products (20 kD linear PEG linked to the N-terminal
methionyl residue of G-CSF) relative to the current 2nd IS for G-
CSF (code 09/136), which is available (Wadhwa et al., 2011), in
an in vitro cell based bioassay using the G-CSF responsive cell-
line, G-NFS-60. Our results indicated that the PEGylated
products were less potent than the current WHO 2nd IS for G-
CSF (representing the unmodified parent molecule) in the
in vitro assay, however, preliminary data derived from dose
response curves comparing the current WHO 2nd IS for G-CSF
and PEG-G-CSF products suggested that the current IS for G-CSF
(Fig. 1) or alternatively, a PEG-G-CSF standard with a unitage
traceable to the current IS for G-CSF may potentially serve as
the IS for PEG-G-CSF products.
Based on the above premise, we further evaluated in an
international collaborative study, two candidate PEG-G-CSF
preparations relative to the currentWHO 2nd IS for G-CSFwith
the aim of selecting and characterising a suitable WHO IS forin vitro bioactivity and for assigning a unitage for in vitro
biological activity of PEG-G-CSF. To achieve this, the study
sought a) to assess the suitability of the currentWHO2nd IS for
G-CSF (as a reference standard for the biological activity of PEG-
G-CSF) or a candidate preparation of human PEG-G-CSF to
serve as the 1st IS for the bioassay of human PEG-G-CSF by
assaying their biological activity in a range of routine, ‘in-house’
bioassays, b) to assess the activity of the ampouled PEG-G-CSF
preparations in different bioassays in current use for these
materials and to calibrate the candidate PEG-G-CSF IS (if
possible) against the currentWHO 2nd IS for G-CSF (09/136) if
theWHO2nd IS for G-CSF is not suitable as a reference standard
for PEG-G-CSF preparations and c) to compare the ampouled
PEG-G-CSF preparations with characterised ‘in-house’ laborato-
ry standards of PEG-G-CSF where these are available.
2. Materials and methods
Two preparations of PEG-conjugated human sequence
recombinant G-CSF, both pure and expressed in E. coli and in
large amounts were kindly donated to WHO for development
of a reference standard (see Acknowledgements). Limited
amounts of conjugated protein were provided to NIBSC by
another manufacturer for evaluation in bioassays. Trial fills
were conducted from the materials (supplied for reference
standard) and the biological activity of the lyophilized
preparations was compared with the bulk materials in a
bioassay based on G-CSF induced proliferation of a murine
myeloid cell-line, G-NFS-60which is a G-CSF responsive variant
of the parent NFS-60 cell-line. This bioassay was also used in
the collaborative study for the current WHO 2nd IS for G-CSF
(Wadhwa et al., 2011). As the trial lyophilizations of PEG-G-CSF
were performed appropriately in the bioassay, final lyophiliza-
tion of different PEG-G-CSF preparations into ampoules was
carried out at NIBSC as per the procedures used for Interna-
tional Biological Standards (ECBS guidelines — WHO Expert
Committee on Biological Standardization, 2006).
Buffers with excipients as shown in Table 1, were prepared
using nonpyrogenic water and depyrogenated glassware.
Buffer solutions were filtered using sterile nonpyrogenic
filters (0.22 μM Stericup filter system, Millipore, USA) where
appropriate.
Table 1
Materials used in study.
Ampoule code Fill date Study code No. of ampoules
in stock
Protein Protein
(predicted Mass – μg)
Expression system Excipients
12/222 1/11/12 B, C 4700 PEG-G-CSF 1 E. coli Trehalose,
Tween 20,
Phenylalanin,e
Arginine,
Human serum albumin
12/188 13/9/12 A 4700~ PEG-G-CSF 1 E. coli
09/136 2/07/09 2nd IS G-CSF 3400~ G-CSF 1 E. coli
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and C are duplicates of the same preparation 12/222 (Table 1).
The mass content of the preparations was determined by the
manufacturers. As the protein content of the ampoules cannot
be verified by direct measurement of absolute mass, the
content is assumed to be the theoretical mass, calculated from
the dilution of the bulk material of known protein mass
content, and the volume of formulated solution delivered to the
ampoule. This mass value is given as “predicted μg”.
For both preparations, a solution at a concentration
predicted as 1 μg/ml PEG-G-CSF was distributed in 1.0 ml
aliquots, giving the theoretical protein content per ampoule
shown in Table 1.
The precision of filling of ampoules had a CV in the range of
0.163–0.305% as assessed by determination of mean fill
weights of all preparations. Each solution was lyophilized, and
the ampoules were sealed under dry nitrogen by heat fusion of
the glass and stored at−20 °C in the dark. The mean residual
moisture of each preparation, measured by the coulometric
Karl–Fischer method (Mitsubishi CA100, A1-Envirosciences
Ltd, Luton, UK), varied between 0.205 and 0.279% for all
preparations. Mean headspace oxygen content determined by
frequency modulated spectroscopy using the Lighthouse FMS-
760 Instrument (Lighthouse Instruments, LLC) varied from0.13
to 0.19 for all preparations. Testing formicrobial contamination
using the total viable count method did not show any evidence
of microbial contamination.
2.1. Participants
Twenty-three participants from eleven countries contribut-
ed bioassay data used for the study (Table 2). The participants
included 3 control, 2 pharmacopoeial, 16 manufacturers' and 2
contract research organisation laboratories.
2.2. Study design and assay methods
Participants were asked to bioassay all samples including
the current WHO 2nd IS for G-CSF (09/136) concurrently on a
minimum of three separate occasions using their own routine
bioassaymethodswithin a specified layout which allocated the
samples across 3 plates and allowed testing of replicates as per
the specified study protocol. It was requested that participants
perform eight dilutions of each preparation using freshly
reconstituted ampoules for each bioassay and include 09/136
and their own in-house standardwhere available on each plate.
A summary of the methods used in the study is given in
Table 3. Amajority of participants used cell-lines and read-outs
that are commonly used for G-CSF bioassays (Wadhwa et al.,
2011).Participating laboratories were sent five sets of three study
samples coded A–C along with the current WHO 2nd IS for G-
CSF (09/136) as detailed in Table 1. Samples B and C were
coded duplicate samples of the same material (candidate
standard 12/222).
Participants were requested to return their raw bioassay
data, using spreadsheet templates provided, and also their own
calculations of potency of the study samples relative to the 2nd
IS for G-CSF.
2.3. Statistical analysis
Relative potencies of the study samples were calculated by
analysis of the raw data at NIBSC using the EDQM CombiStats
software (Combistats V5.0. EDQM). All bioassayswere analysed
using a simple parallel-line model based on a linear section of
the dose response range (Finney, 1978). In the majority of
laboratories, no transformation of the bioassay response was
applied. For the laboratories 5 and 14, a log transformation of
the bioassay response was used. Validity of the bioassay was
assessed by calculation of the ratio of slopes for the two test
samples under consideration. The samples were concluded to
be non-parallel when the slope ratio was outside of the range
0.80–1.25 and no potency estimates were calculated.
Potency estimates from all valid bioassays were combined
to generate an unweighted geometric mean (GM) for each
laboratory and these laboratory means were used to calculate
an overall unweighted geometric mean for each sample.
Variability between bioassays within laboratories and between
laboratories has been expressed using geometric coefficients of
variation (GCV = {10s − 1} × 100% where s is the standard
deviation of the log10 transformed estimates). Analysis of
variance with Duncan's multiple range test (Duncan, 1975)
using the log transformed potency estimates was used to
compare laboratories and samples (p b 0.05 used to conclude
significance).
The agreement between duplicate samples was assessed by
calculating the difference in log potency estimates (relative to
sample A) of samples B and C for each assay, calculating the
mean of the squared difference for each laboratory, taking the
square root to give a root mean square (RMS) value, and
expressing this as an average percentage difference.
2.4. Stability studies
Samples of the candidate standard 12/188 were stored at
elevated temperatures (20 °C, 37 °C and 45 °C) for seven
months and tested concurrently with those stored at the
recommended storage temperature of −20 °C, and baseline
samples stored at−70 °C. A total of six independent bioassays
were performed, with three plates per assay. The potencies of
Table 2
List of participants.
The following participants contributed data to the study. In this report, each laboratory has been identiﬁed by a number from 1 to 24 that is not related to this
order of listing.
Xinchang Shi and Rao Chunming, Division of Biopharmaceuticals, National Institutes for Food and Drug Control (NIFDC), 2 Tiantan Xili, Beijing 100050,
P.R. China
Till Koenig, Novartis Pharma AG,WKL-681.3.05, 4002 Basel, Switzerland
Beate Hartung and Sonja Klingelhoefer, Biological Assays, Richter-Helm-Biologics, Suhrenkamp 59, D-22335 Hamburg, Germany
Taina Cruz, Amgen Manufacturing Limited, Road 31 Km 24.6, Juncos, PR 00777-4060, Puerto Rico
Chris Bird, Cytokines and Growth Factors Section, Biotherapeutics Group, NIBSC, South Mimms, Herts, EN6 3QG, UK
Meihua Yang and Zeng Yan, Xiamen Amoytop Biotech Co. Ltd, No. 330, Wengjiao Road, Haicang, Xiamen, Fujian, P.R. China, 361022
Andrea López, Federico Parnizari, Control calidad biológico, Laboratorios Clausen S.A., Bv. Artigas 3896, Montevideo CP 11700, Uruguay
Cecilia Medrano, Bioch., Head of Quality Control, Gema Biotech S.A., Fray Justo Sarmiento 2350 ediﬁcio 2B 5 piso B1636AXK, Olivos, Buenos Aires, Argentina
Dong-Yeon Kim, Chankyu Lee, Bio Engineering Lab., Chong Kun Dang Pharm., 464-3, Jung-dong, Yongin Si Giheung-gu, Gyeonggi-Do, Seoul 446-916,
Rep. of Korea
MN Dixit, Manjunath Patil, Bioanalytical Laboratory, 3rd Floor Clinigene International Limited, Clinigene House, Electronics City, Phase 2,
Bangalore 560100, India
Zeljka Antolvic, Ela Kosor Krnic, Hospira Zagreb d.o.o., Prudnicka cesta 60,10291 Prigorje Brdovecko, Croatia
Subba Raju BV, Sahana S, Shridhar Bagal, Amit Inchal, Quality control-QC-Q8, B1 block, Biocon Limited, Biocon Park, Jigani Link Road, Plot 2, 3 & 4
Bommasandra IV Phase, Bangalore 560 099, India
Himanshu Gadgil, Intas Biopharmaceuticals Ltd., Plot No. 423/P/A, Sarkhej-Bavla Highway, Village-Moraiya, Taluka – Sanand, Ahmedabad 382213,
Gujarat, India
Susobhan Das, Biologics & Biotechnology Division, United States Pharmacopeia-India (P) Ltd, Plot No. D6 & D8, IKP Knowledge Park, Genome Valley,
Shameerpet, Hyderabad 500078, RR District, Andhra Pradesh, India
Veena Raiker and Alok Sharma, Research and Development, Lupin Ltd, Biotech Division, Gat #1156, Ghotawade Village, Mulshi Taluka, Pune 412 115,
Maharashtra, India
Renu Jain and Shalini Tewari, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62 (Institutional Area), NOIDA 201 307, Uttar
Pradesh, India
Sridevi Khambhampaty, Manish Reddy, Biologics Development Centre, Dr Reddy's Laboratories, Survey No: 47, Bachupally, Qutubullapur, RR Dist 500090,
Andhra Pradesh, India
Sanjay Bandyopadhyay, Zydus Research Centre, Biotech Division, Cadila Healthcare Ltd.,
Sarkhej-Bavla N. H. 8A, Moraiya. Tal: Sanand, Ahmedabad 380015, Gujarat, India
Kwanyub Kang, Mogam biotechnology research institute, Greencross Corp., 341 Bojeong-dong, Giheung-gu, Yongin, 446-799, Rep. of Korea
Michael Ambrose, US Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852, USA
Swarnendu Kaviraj, Analytical Development, Vaccine Formulation and Research Center,
Gennova Biopharmaceuticals Ltd, BTS 2 Building Chrysalis Enclave Block 2, International Biotech Park, I.T.B.T. Park Phase II Hinjewadi MIDC, Pune,
Maharashtra 411057, India
Zhang Xuan, Tianjin PEGylatt Biotechnology Co.,Ltd., Lab Buiding N1801, International Joint Academy Of Biotechnology &Medicine, 220 Dongting Road, TEDA,
Tianjin, P.R. China, 300457
Mr Yanzhuo Wu, Technology Center, Beijing SL Pharmaceutical Co., Ltd, No.69, Fushi Road, Haidian District, Beijing, P.R. China
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baseline samples. In addition, the stability of the samples at
4 °C and 20 °C after a period of 24 h and 1 week following
reconstitution and after a series of freeze–thaw cycles (1 up to
4) was assessed. Three independent bioassays were performed
for 12/188, with each bioassay consisting of three plates. All
studies were conducted at NIBSC using the GNFS-60 assay.3. Results
23 laboratories submitted data. Each participating labora-
tory has been assigned a code number allocated at random, and
not necessarily representing the order of listing in Table 2 to
retain confidentiality in the report.
The majority of the laboratories returned data from three
bioassays as requested, using three plates per assay. Laborato-
ries 4, 6, 11 and 20 performed four assays, using three plates
per assay. Laboratory 2 returned data from three assays, using
four plates per assay. Laboratory 13 returned data from six
assays, using three plates per assay. Laboratory 21 performed
two assays, using four plates per assay. Laboratories 16 and 22
each performed one bioassay using four plates. For laboratory
3, responses in plate columns 2 and 11were excluded from the
analysis as these showed a clear plate effect giving a lower level
of response.In general, acceptable parallelismwas achieved between all
study samples as indicated by the slope ratios obtained in a
majority of laboratories using the bioassays employed in the
study. However, there was a greater tendency towards non-
parallelism when the candidate preparations coded A, B and C
were comparedwith the currentWHO2nd IS for G-CSF, 09/136
(16.0%, 20.1% and 19.2% of cases respectively), as opposed to
comparisons of B or C relative to A. This is partly due to greater
variability in the slope ratios when comparing the candidate
PEG-G-CSF preparations against the currentWHO 2nd IS for G-
CSF rather than among themselves and steeper slopes observed
for samples A, B and C compared to the IS in some laboratories.
For example, slope ratios for sample B relative to theWHO 2nd
IS for G-CSF (09/136) had aGCVof 20.2%while slope ratios for B
relative to A had a GCV of 12.7%. Laboratory 5 was noted as
obtaining steeper slopes for samples A, B and Cwhen compared
with 09/136 in all assays. A similar pattern of generally steeper
slopes for samples A, B and C was observed in laboratories 7
and 20. However, no overall trend in slope ratios across all
laboratories was observed.3.1. Potencies of samples A, B and C relative to IS 09/136
Relative potency estimates for samples A–C relative to 09/
136 are summarised in Table 4 and Fig. 2.
Table 3
Brief details of bioassays contributed to the study.
laboratory Code Bioassay cell line** Assay type Assay duration (h) Assay readout
1 MNFS-60 Proliferation 24 Luminescence (cell-titer Glo)
2 NFS-60 Proliferation 34–38 Colorimetric (MTS)
3 G- CSFRLuc Reporter-gene 3–4 Luminescence (luciferase)
4 NFS-60 Proliferation 26–30 Fluorescence (Alamar Blue)
5 NFS-60 Proliferation 40–48 Colorimetric (MTT)
6 GNFS-60 Proliferation 48 3H Thymidine
7 NFS-60 Proliferation 48 Colorimetric (MTS)
8 NFS-60 Proliferation 48 Colorimetric (Cell Titer96 Aqueous One, MTS)
9 MNFS-60 Proliferation 44 Colorimetric (WST-1)
10 MNFS-60 Proliferation 44–48 Colorimetric (Cell Titer96 Aqueous One, MTS)
11 MNFS-60 Proliferation 40–44 Fluorescence (Alamar Blue)
12 MNFS-60 Proliferation 44 Colorimetric (MTS)
13 MNFS-60 Proliferation 42–44 Fluorescence (Alamar Blue)
14 MNFS-60 Proliferation 48 Colorimetric (MTS)
15 MNFS-60 Proliferation 44 Luminescence (Cell-titer Glo)
16 NFS-60 Proliferation 20–22 Colorimetric (MTT)
18 NFS-60 Proliferation 48 Colorimetric (MTS)
19 MNFS-60 Proliferation 44 Colorimetric (MTS)
20 MNFS-60 Proliferation 28–32 Luminescence (Cell-titer Glo)
21 NFS-60 Proliferation 48 Colorimetric (MTT)
22 NFS-60 Proliferation 48 Colorimetric (MTT)
23 MNFS-60 Proliferation 44 Colorimetric (MTS)
24 MNFS-60 Proliferation 48 Colorimetric (Cell Titer96 Aqueous One, MTS)
Table 4
Potencies of samples A, B and C relative to IS 09/136.
Lab Sample A Sample B Sample C
GM GCV n GM GCV n GM GCV n
1 0.24 10.0 8 0.23 5.0 7 0.23 17.4 8
2 0.66 14.3 12 0.71 15.9 11 0.71 10.4 12
3 0.55 21.7 9 0.53 16.3 9 0.61 13.7 9
4 0.33 8.0 12 0.32 9.9 12 0.32 8.4 16
5 1.00 14.4 6 0.96 10.4 6 0.95 7.0 4
6 0.39 13.2 14 0.36 17.8 14 0.38 17.5 15
7 0.85 22.9 7 0.90 22.9 4 0.95 . 2
8 1.39 19.4 8 1.28 9.1 6 1.27 20.9 8
9 0.38 27.5 5 0.31 27.0 3 0.39 20.4 6
10 0.26 14.0 8 0.25 9.8 9 0.24 13.6 8
11 0.36 14.4 11 0.34 18.6 11 0.35 11.9 11
12 0.40 10.5 4 0.38 7.8 6 0.38 12.8 9
13 0.27 11.2 17 0.25 17.2 16 0.26 13.1 17
14 0.37 16.6 9 0.40 21.9 8 0.39 13.8 11
15 0.24 7.3 9 0.22 9.6 9 0.23 7.9 12
16 0.36 40.9 3 0.45 36.0 3 0.36 44.5 4
18 1.09 25.2 8 1.02 37.8 8 1.00 33.8 8
19 0.41 12.3 6 0.34 35.4 7 0.29 3.0 3
20 0.30 18.7 8 0.26 23.9 9 0.28 23.3 9
21 1.08 63.4 4 1.30 67.6 5 1.40 44.3 8
22 1.33 . 1 2.15 . 1 1.44 . 1
23 0.35 44.6 7 0.26 24.9 5 0.36 46.3 6
24 0.58 19.0 8 0.61 18.9 6 0.59 15.5 6
GM
(95% CI)
0.49
(0.38–0.62)
0.48
(0.36–0.63)
0.48
(0.37–0.63)
Between-lab GCV 76.0 92.6 83.3
GMa 0.44 0.42 0.43
GMb
(95% CI)
0.35
(0.30–0.40)
0.32
(0.27–0.38)
0.34
(0.29–0.40)
Between-lab GCVb 30.2 34.8 34.8
GMa,b 0.34 0.32 0.33
GM— geometric mean.
CI— confidence interval.
GCV — geometric coefficient of variation (%).
n — number of estimates used in calculation.
a Calculated as geometric mean of all individual assay estimates.
b Excludes laboratories 2, 5, 7, 8, 16, 18, 21 and 22.
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Fig. 2. Laboratory mean potencies of samples A, B and C relative to the current IS for G-CSF (09/136).
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laboratory GCVs shown in Table 4, ranged from 3.0% (labora-
tory 19, sample C) to 67.6% (laboratory 21, sample B). In the
majority of cases, GCVs were less than 30%, with seventeen
laboratories achieving this for all test samples.
Inter-laboratory variability, as measured by the between-
laboratory GCVs shown in Table 4, indicated a high level of
variability between laboratories (76.0%, 92.6% and 83.3% for
samples A, B and C respectively). For all samples, laboratories 5,
7, 8, 18, 21 and 22 gave significantly higher estimates than all
the other laboratories (p b 0.05). As these laboratories used the
same bioassaymethod, the NFS60 cell-line based bioassaywith
a colorimetric readout, overall means were also calculated
excluding these laboratories, together with laboratories 2 and
16 who also used this method. Inter-laboratory variability was
reduced, giving GCVs of 30.2%, 34.8% and 34.8% for samples A, B
and C respectively. Overall mean relative potencies were
reduced by around 30% following the exclusion of these
laboratories.3.2. Potencies of samples B and C relative to A
Relative potency estimates for samples B and C (which are
coded duplicates of the same preparation) relative to A are
summarised in Table 5 and Fig. 3. The potency estimates of these
samples showed high concordance (0.99 and 1.02 for B and C
respectively) relative to A.
Intra-laboratory variability, as measured by the within-
laboratory GCVs shown in Table 5, ranged from 3.2% (labora-
tory 15, sample C) to 55.4% (laboratory 16, sample B). In the
majority of cases, GCVs were less than 30%, with eighteen
laboratories achieving this for both test samples.
Inter-laboratory variability, as measured by the between-
laboratory GCVs shown in Table 5, indicated excellent agree-
ment between laboratories (10.1% and 8.7% for samples B and C
respectively). Exclusion of laboratories 2, 5, 7, 8, 18, 16, 21 and22 as noted above gave a between-laboratory GCV of 5.7% for
both samples B and C.3.3. Agreement between duplicates, B and C
Samples B and C were coded duplicates of the same
material. The overall potency estimates for these samples
relative to sample A were in very close agreement (0.99 and
1.02 respectively with a mean value of 1.01).
The agreement between the potency estimates of B and C
within bioassays can be assessed in twoways. Firstly, the intra-
laboratory GCVs for the potencies of sample C relative to
sample B, shown in Table 5, represent the variability between
bioassays of direct comparisons of C to B. They range from 4.2%
(laboratory 15), representing excellent agreement between
assays, to 48.8% (laboratory 19), which represents a higher
level of variability. Eighteen laboratories had GCVs less than
30%. Secondly, as described in the Statistical analysis section,
the average difference in potency estimates of samples B and C
was calculated (rootmean square difference in log potency) for
each laboratory, and these differences, expressed as a percent-
age ranged from 5.0% (laboratory 5) to 41.1% (laboratory 19),
with 16 laboratories having a value less than 20%.3.4. Comparison of study samples with in-house standards
Intra-laboratory variability for in-house standards relative
to samples A, B and C is summarised in Table 6. Slope ratios
from individual plates are shown in Fig. 4. Bioassays performed
on the first day by laboratory 21 are not shown as the slope
ratios were b0.30 in all bioassays on this day.
Slope ratios showed non-parallelism in 16.2% of cases.
Exclusion of laboratories 2 and 20 which used the unmodified
GCSF protein as an in-house standard gave non-parallelism
in only 14.7% of cases. In general, acceptable parallelism was
Table 5
Relative potencies of samples A, B and C.
B relative to A C relative to A C relative to B
(coded duplicates)
Lab GM GCV n GM GCV n GM GCV n
1 0.99 8.1 9 0.98 16.7 9 0.99 14.7 9
2 1.08 11.7 11 1.07 14.9 11 1.00 10.8 11
3 0.97 8.6 9 1.10 24.1 9 1.14 16.5 9
4 0.97 8.6 12 0.97 7.3 12 1.00 8.2 12
5 0.97 6.1 9 0.99 7.4 9 1.03 5.5 9
6 0.96 13.6 20 1.00 14.5 20 1.01 12.9 12
7 0.99 25.4 8 1.08 28.7 7 1.14 38.6 9
8 0.92 31.8 8 0.86 21.8 8 1.09 11.9 8
9 0.99 26.9 6 1.07 17.9 6 0.96 35.8 4
10 0.98 8.6 9 0.94 12.7 9 0.96 11.0 9
11 1.00 9.9 11 0.99 12.1 12 0.99 12.3 11
12 1.00 11.1 8 1.00 8.7 8 1.04 8.7 9
13 0.92 16.0 18 0.96 8.7 18 1.05 12.8 18
14 1.06 13.4 9 1.10 8.0 9 1.04 17.0 9
15 0.89 5.6 9 0.96 3.2 9 1.08 4.2 9
16 1.24 55.4 3 1.17 13.3 3 0.94 39.5 3
18 0.95 22.6 9 0.96 14.0 7 1.05 15.9 8
19 0.90 37.8 9 1.07 42.4 5 1.04 48.8 6
20 0.87 27.0 12 0.95 22.8 11 1.08 27.4 12
21 0.97 28.4 6 0.98 16.9 5 0.94 20.4 4
22 1.33 33.3 3 1.27 23.2 2 1.16 . 1
23 1.03 9.4 5 1.00 6.7 6 1.00 11.2 8
24 0.99 30.9 7 1.08 14.8 9 1.09 26.7 7
GM
(95% CI)
0.99
(0.95–1.04)
1.02
(0.99–1.06)
Between-lab
GCV 10.1 8.7
GMa 0.97 1.01
GMb
(95% CI)
0.97
(0.94–1.00)
1.01
(0.98–1.04)
Between-lab
GCVb 5.7 5.7
GMab 0.96 1.00
GM— geometric mean.
CI— confidence interval.
GCV — geometric coefficient of variation (%).
n — number of estimates used in calculation.
a Calculated as geometric mean of all individual assay estimates.
b Excludes laboratories 2, 5, 7, 8, 16, 18, 21 and 22.
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samples A, B and C.
Excluding laboratory 18, intra-laboratory variability as
measured by the within-laboratory GCVs shown in Table 6,
ranged from 5.7% (laboratory 15, sample A) to 39.7% (labora-
tory 3, sample C). In the majority of cases, GCVs were less than
30%, indicating a comparable level of variability to that
observed for the common samples tested by all laboratories in
the study.
3.5. Stability studies
Geometric mean potency estimates of samples of the
candidate standard 12/188 stored at elevated temperatures for
over 7 months (expressed relative to those stored at −70 °C)
are shown in Table 7. No detectable loss of potency is detected,
even at 45 °C. Therefore, it is not possible to predict a yearly loss
for this preparation.
Further studies showed that the potency of 12/188 is not
diminished after a week of storage at either 4 °C or 20 °C
following reconstitution or after a limited number of freeze–thaw cycles (up to 4 cycles) suggesting that the preparation is
sufficiently stable to serve as an international standard (data
not shown).
4. Discussion
It is well recognised that PEGylation can variably reduce
potency in vitro while increasing half-life in vivo and, therefore,
assessment of these products in practice would require in
addition to potency evaluation by in vitro bioassays, determina-
tion of the pharmacokinetic activity of the PEG-G-CSF product.
Here, we have focussed on the development of a reference
standard for determination of in vitro biological activity of PEG-
G-CSF following a demand frommanufacturers worldwide for a
bioactivity standard for PEG-G-CSF products.
Although the approved PEGylatedG-CSF product is dosed in
mass units and the label does not provide any information
relating to its biological activity (i.e., international unit or
specific activity of protein), it is a regulatory requirement to
determine the bioactivity in vitro for lot release and stability
assessment using an appropriate reference standard. Guidance
Fig. 3. Laboratory mean potencies of samples B and C relative to A.
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ling of biological medicinal products that contain modified
proteins is available (EMA/CHMP/BWP/85290/2012; EMEA/
CPMP/BWP/3068/03).
Some manufacturers have measured the potency of their
PEGylated G-CSF products in bioassays calibrated using the
current WHO 2nd IS for G-CSF (09/136) but the suitability of
reporting potencies in the respective IU has not been formally
established. Since many PEGylated G-CSF products currently in
development have a 20 kD linear PEG attached to theN-terminal
methionyl residue of G-CSF (INN Filgrastim) and use a
conjugation process and coupling chemistry similar to thatTable 6
Intra-laboratory variability for in-house standards (IH) relative to samples A, B
and C.
IH relative to A IH relative to B IH relative to C
Lab GCV n GCV n GCV n
1 7.9 9 12.4 9 18.5 9
2 15.2 9 23.3 7 21.9 7
3 27.1 9 30.3 9 39.7 9
4 5.8 12 9.8 12 7.8 16
8 12.9 7 20.9 7 24.0 11
9 10.6 7 38.0 5 23.9 6
10 10.1 9 10.3 9 10.6 9
11 17.3 12 15.0 10 23.1 12
12 10.7 8 6.2 7 8.8 10
13 9.1 15 11.6 16 10.7 16
14 13.1 9 11.0 8 16.8 12
15 5.7 9 9.6 9 7.8 12
16 37.0 3 21.6 3 18.6 4
18 187.8 6 168.9 7 138.7 5
20 24.9 6 29.6 5 24.9 8
21 1 24.4 2 18.7 5
22 1 1 35.6 3
23 13.2 6 10.5 8 11.6 8
24 22.3 9 36.7 7 29.4 9
GCV — geometric coefficient of variation (%).
n — number of estimates used in calculation.employed for the licenced innovator product (INN PEG-
Filgrastim), two candidate preparations specifically representing
these types of PEGylated G-CSF products were assessed in this
collaborative study.
The candidate PEG-G-CSF preparations were evaluated
relative to the current WHO 2nd IS for G-CSF using in vitro
biological activity assays for G-CSF with the aim of
a) determining the suitability of the current WHO 2nd IS for
G-CSF (the standard for the parentmolecule) or alternatively, a
PEG-G-CSF candidate preparation to serve as the reference
standard for biological activity of PEG-G-CSF products and
b) assigning a unitage to the reference PEG-G-CSF standard
should the WHO 2nd IS for G-CSF not be suitable. A strategy
involving three options was formulated (Table 8) at the outset
as the basis for assigning a unitage to the PEG-G-CSF standard.
With the exception of a single laboratory which used a
luciferase reporter gene assay, most laboratories performed
bioassays based on G-CSF-induced proliferation of the NFS-60
cell-line or its variants,M-NFS-60 or G-NFS-60. These bioassays
were used previously in the study for theWHO2nd IS for G-CSF
and employ different readouts for detection, for example, a
radioactive label (3H-thymidine) or a colorimetric/fluorescence
dye (Wadhwa et al., 2011).
Results from this study showed that acceptable parallelism
was achieved between all study samples as indicated by the
slope ratios obtained in a majority of laboratories using the
bioassays employed in the study. However, there was a greater
tendency towards non-parallelism when the candidate prepa-
rations coded A, B and C were compared with the 2nd IS for G-
CSF, 09/136 (containing unmodified G-CSF), as opposed to B or
C relative to A. While this is partly attributed to the higher
variability in the slope ratios when comparing the candidate
samples against the WHO 2nd IS for G-CSF rather than among
themselves and steeper slopes for samples A, B and C compared
to the IS in some laboratories, the low potency of PEG-G-CSF
relative to the WHO 2nd IS for G-CSF is also a likely
contributory factor to the non-parallelism seen in some
a)
b)
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Fig. 4. Slope ratios for in-house standards (IH) relative to samples A, B and C as shown in panels a, b and c.
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Table 7
Potency estimates for candidate standard 12/188 stored at elevated tempera-
tures for 7 months relative to ampoules stored at−70 °C.
Storage temperature Potency relative to−70 °C
GM 95% CI GCV n
−20 °C 1.03 0.98–1.09 11.0 18
+20 °C 1.03 0.98–1.09 10.9 18
+37 °C 0.99 0.95–1.03 8.9 18
+45 °C 1.05 1.01–1.09 8.3 18
GM— geometric mean.
CI— confidence interval.
GCV — geometric coefficient of variation (%).
n — number of estimates used in calculation.
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Fig. 5. Comparison of PEG-G-CSF preparations (W–Z) relative to the IS for PEG-
G-CSF (coded 12/188) using the GNFS-60 cell-line.
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across all laboratories was observed.
In most laboratories, the PEGylated candidate preparations
had a reduced potency in comparison with theWHO 2nd IS for
G-CSF. While the bioassays from many laboratories showed
very similar results for potencies of samples A–C relative to 09/
136 (GM potency of 0.49 for A or 0.48 for B and C) as shown in
Table 4 and Fig. 2, a high variability (GCV ranging from 76 to
93%) depending on the sample being compared was observed.
This was because data from some laboratories, in particular
those using the NFS-60 cell-line and the colorimetric readout,
MTT/MTS showed significantly higher potency estimates
relative to other laboratories. Such high estimates were not
evident for laboratory 4 which used the NFS-60 and a
fluorescence dye, Alamar Blue for detection. Although the
reason is not clear, it is possible that differences in sourcing and
maintenance of the NFS-60 cells result in insensitivity and
inability of the NFS-60 cell-line to discriminate between the
modified and unmodified G-CSF in some laboratories. In
contrast, the variant cell-lines, G-NFS-60 or M-NFS-60 are
highly sensitive to G-CSF and capable of distinguishing
between the two G-CSF forms. It is possible that the use of the
colorimetric dye is also a likely contributory factor as bioassays
using MTT which forms an insoluble precipitate requiringTable 8
Assigning a unitage to the PEG-G-CSF standard.
Option Question Answer Pros
1 Should the unitage
be traceable to the IS
for G-CSF?
Possible — Study includes 2nd IS for
G-CSF but the traceability issue to
be determined by statistical analysis
of data. If bioassays valid relative to
the IS, units can be traceable
to G-CSF IS.
Traceable
Align wit
approach
Likely to e
PEG-G-CS
of in-hou
WHO 2nd
Provides
2 Should the standard
be assigned
independent units?
Will be determined by statistical
analysis of study data as described
above. If data relative to G-CSF IS
is inappropriate and gives statistically
invalid estimates, independent units
likely to be assigned.
Usual and
No impac
of current
3 Assign independent
units and indicate
relationship with
G-CSF IS
Possible — Study includes 2nd IS
for G-CSF. Will be determined by
statistical analysis of study data as
described above.
Ideal app
well as a
conseque
May be su
Provides
other mo
moleculesolubilisation as opposed to bioassays using the soluble MTS
formazan product (Buttke et al., 1993) were generally
associated with a high variability. If data from the laboratories
using NFS-60 and the colorimetric dye (n = 8) are excluded,
the between-laboratory variability in the potency estimates is
diminished to 30–35% (from GCV of 76–93%).
If expressing unitage for sample A (candidate PEG-G-CSF
preparation) in terms of the current WHO 2nd IS for G-CSF, a
relationship is evident as shown in Table 4. Based on the high
variability and thebias in potency estimates if NFS-60 bioassays
are considered, a mean potency of 0.35 can be derived by
excluding these assays. Since the currentWHO2nd IS for G-CSF
(09/136) has an assigned unitage of 95,000 IU per ampoule, the
mean potency estimate for sample A is equivalent to 33,250 IU
of G-CSF per ampoule. However, it should be noted that there is
no formal relationship or conversion factor between the units
for PEG-G-CSF and the units for the current WHO 2nd IS for
G-CSF (coded 09/136).Cons
to G-CSF IS
h other products if this
has been used
ncourage developers of novel
F products to consider calibration
se reference standards using the
IS for G-CSF, if possible
objectivity for independent testing
Difﬁcult to ensure similar
relationship between the
two standards and between
PEG-G-CSF products and
G-CSF IS
Risk of discontinuity when
G-CSF IS is replaced
easy approach
t in case of replacement
G-CSF IS
Risk of disconnection with
novel PEG-G-CSF & other
modiﬁed G-CSF products
Potential for confusion for
users
roach — provides an independent unitage as
relationship with G-CSF IS (and
ntly a link with the parent molecule).
itable for novel PEGylated G-CSF products
a basis for linking novel PEG-G-CSF and
diﬁed G-CSF products to the parent
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used as a standard for comparison purposes, the variability in
potency estimates of samples B and C is markedly reduced and
there is excellent inter-laboratory agreement between poten-
cies for B and C (coded duplicates of the same preparation)
relative to A (Table 5). This reduction in variability when using
A as a comparator is not unexpected as sample A is PEGylated in
a similar fashion as samples B and C and is, therefore, highly
similar to B and C in terms of its molecular species and
structural entity as opposed to the parent protein, G-CSF. In this
instance, no data were excluded as the potency estimates were
not significantly different between laboratories.
The calibration of procedures is highly dependent on the
quality and characteristics of the standard preparation used.
The principle of comparing ‘like-with-like’ is well established
for the bioassay of biological materials and such comparisons
give better agreement as seen when sample A is used for
calculating relative potencies of the different preparations B
and C.
Data derived from coded duplicates, samples B and C were
also highly consistent. The overall potency estimates relative to
A were in very close agreement (0.99 and 1.02 respectively
with a mean value of 1.01). There is also good agreement
between the laboratory mean estimates of samples B and C
(Table 5) for most laboratories.
Several participants (n = 18) assayed their in-house
standards in the bioassayswhich provided an ideal opportunity
to evaluate the behaviour of these in-house preparations
relative to the candidate preparations. Although two laborato-
ries used G-CSF preparations, a majority of participants (n =
16) included PEG-G-CSF preparations (manufactured in-house
in many cases) as an in-house standard in their bioassays and
provided brief information about these preparations (n = 15).
While a major proportion of these preparations (n= 12) were
representative of the candidate materials, three preparations
were different in terms of the size of PEG or conjugation site.
Slope ratios as shown in Fig. 4 indicate that, in general,
acceptable parallelism was evident for the comparison of in-
house standards and candidate standards. Levels of intra-
laboratory variability were comparable to those observed for
the common samples tested by all laboratories in the study.
Stability studies have shown that the potency of the
preparation, coded 12/188 is not diminished after 1 week of
storage at either 4 °C or 20 °C following reconstitution or after
repeated freeze–thaw cycles. Results from stability studies at
7 months suggest that 12/188 is likely to be highly stable under
long term storage conditions at −20 °C. However, it is noted
that because of the short duration of this study and the lack of
detectable degradation of PEG-G-CSF, it is impossible to predict
the degradation rate of the proposed standard. Therefore, it will
be a future requirement to assess the stability of PEG-G-CSF in
the residual ampoules that have remained in storage at
elevated temperatures.
These results clearly indicate that the candidate PEG-G-CSF
preparation A, coded 12/188 can be used as a reference
standard for in vitro bioactivity of PEGylated G-CSF prepara-
tions (that are manufactured to be representative of the
approved product, INN PEG-Filgrastim). Dose response curves
of different PEG-G-CSF products relative to the PEG-G-CSF
reference standard are illustrated in Fig. 5. It was proposed to
the WHO ECBS that the candidate preparation (sample A,coded 12/188) be established as the WHO 1st IS for in vitro
bioactivity of PEG-G-CSF with an assigned value of 10,000 IU/
ampoule for biological activity. This unitage is arbitrary and
unrelated to the unitage for the current WHO 2nd IS for G-CSF.
Of note, since 12/188 has only been evaluated for use in
in vitro bioassays, it cannot be assumed to be suitable for
evaluation in vivo or for pharmacokinetic studies without
suitable validation.
Since both candidate preparations behaved similarly in the
bioassays, 12/222 would serve as a suitable replacement
standard when stock of the IS, coded 12/188 is exhausted.
Taking the potency of 12/188 to be 10,000 IU/ampoule gives an
estimated potency for 12/222 of 10,100 IU/ampoule.
In principle, the approach used here for defining the unitage
of PEG-G-CSF standard may also be applicable to other modified
proteins, however, this will need to be established on a case-by-
case basis.
5. Conclusions
Based on the results of this study, the PEG-G-CSF preparation
(sample A, coded 12/188) was judged suitable to serve as the
WHO 1st IS for in vitro bioactivity of PEG-G-CSF products (that
are representative of the approvedproduct, INNPEG-Filgrastim).
It was established by the WHO ECBS at its meeting on October
13, 2013 as theWHO1st IS for PEG-G-CSFwith an assigned value
for in vitro biological activity of 10,000 IU/ampoule.
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